SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and a sharp multi-year price decline following a weak outlook and concerns over declining demand in China. While the community remains deeply divided, with some investors betting on a generational value play due to the brand's iconic status and dividend, others are aggressively shorting the stock, citing poor leadership, brand dilution, and concerns that the company's growth model is fundamentally broken.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility and intense social media debate as investors react to the company's pause in Bitcoin accumulation and ongoing concerns regarding stock dilution. The community remains deeply polarized, with bulls pointing to the company's long-term Bitcoin treasury strategy while vocal critics argue that the reliance on equity offerings to fund operations creates an unsustainable path for shareholders.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility following a mixed quarterly report where revenue beat analyst estimates while earnings fell short of expectations. The community remains deeply divided, with bulls pointing to the company's long-term luxury ecosystem strategy and potential tariff relief as major catalysts, while bears warn of ongoing debt pressures, weakening housing trends, and a business model struggling to sustain high-end demand.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing high volatility as investors track its history as a parabolic runner, leading to intense debate over whether it is primed for another short squeeze or remains a high-risk pump-and-dump scheme. Community discussion is heavily focused on the stock's low float, rising cost-to-borrow fees, and speculation regarding potential retail-driven "meme" momentum compared to its past price spikes.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is experiencing intense volatility and downward pressure as investors debate whether the stock is an oversold growth opportunity or a bubble facing a severe consumer discretionary correction. While bullish participants point to the company's aggressive store expansion, share buybacks, and international potential as reasons to buy the dip, bears are aggressively shorting the stock, citing concerns over same-store sales declines, high valuations, and broader fears of consumer exhaustion impacting the restaurant sector.

Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. It offers properties for rent to life science, agriculture technology (agtech), and technology tenants. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Alexandria Real Estate Equities Inc.

Alexandria Real Estate is currently drawing significant investor scrutiny as share prices hover near multi-year lows, triggering a divide between those concerned by high debt levels and structural biotech sector headwinds, and contrarian investors who view the current valuation as an extreme dislocation from the company's underlying property portfolio value. The community is actively debating the sustainability of the dividend and monitoring institutional accumulation patterns, with many participants treating the current price action as a deeply oversold opportunity despite the near-term uncertainty.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant community attention as a new, pure-play vehicle offering direct exposure to SpaceX and other space exploration companies ahead of anticipated industry milestones. Investors are actively debating the fund's early AUM and liquidity, drawing frequent comparisons to other space-themed ETFs and speculating on potential price momentum as interest in commercial space activity intensifies.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and investor speculation as traders debate the potential for a short squeeze, fueled by high short interest and anticipation surrounding upcoming earnings. The community remains sharply divided, with some betting on a long-term turnaround backed by Bill Ackmans significant stake, while others express frustration over persistent share price weakness and the company's substantial debt load.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a significant clinical update regarding its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer. While the stock faced an intraday slump due to concerns over safety signals at higher doses, community discussion remains heavily divided between those viewing the selloff as an exaggerated overreaction with upside potential and those concerned about the broader implications for EZH2-targeting drug classes.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is currently facing significant volatility as investors weigh strong revenue growth and new expansion into physical AI and robotics against concerns over margin compression and high client concentration. The community is actively debating the stock's long-term potential as a defense and AI infrastructure play versus the short-term pressure from market-wide headwinds and the lack of immediate bullish catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.

Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS

Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,316 shar...

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sales potential and competitive positioning.read more...

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays

Barclays increased their price target on shares of Ionis Pharmaceuticals from $95.00 to $106.00 and gave the stock an "overweight" rating in a report on Thursday...

What is HC Wainwright's Estimate for IONS FY2027 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at HC Wainwright issued their FY2027 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.35) pe...

Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price

Needham & Company LLC raised their price objective on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a "buy" rating in a research report on Wednesday...

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright

HC Wainwright increased their price objective on Ionis Pharmaceuticals from $110.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday...

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 5,812 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eugene Schneider sold 5,812 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $70.97, for a total value of $412,477.64. Following the sale, the executive vice...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IONS News

IONSIonis Pharmaceuticals Inc